Stock Movers: Qualcomm, Stryker, Constellation Brands (Podcast)

Qualcomm shares rose as much as 8.7% to $183.49 after it signed a multigeneration agreement to supply customized AI-infrastructure chips to Amazon Web Services; Amazon also received rights to acquire up to $4 billion of Qualcomm stock. Qualcomm expects to begin recognizing revenue in fiscal Q1 and reiterated confidence in reaching $5 billion of data-center revenue in fiscal 2027. Offsetting the positive move, cyberattacks disrupted product deliveries and sales at Boston Scientific and Stryker, sending their shares down as much as 4.9% and 9.1%, respectively, while Constellation Brands fell up to 3.7% to its lowest intraday level since April 2020.

Analysis

QCOM’s AWS design win matters less for near-term revenue than for validating Qualcomm as a credible merchant alternative in AI infrastructure. The embedded equity-acquisition right aligns Amazon with QCOM but also creates a dilution/overhang question: the market should value the contract on incremental gross profit and attach rate across subsequent platforms, not on the headline notional. The key competitive read-through is negative for smaller AI silicon challengers and modestly disruptive to AVGO’s custom-silicon narrative, while the direct earnings risk to NVDA remains limited unless Qualcomm demonstrates deployment beyond a single hyperscaler over the next 2-4 quarters.

The cyber incidents at BSX and SYK create a near-term revenue-recognition problem, but the more important variable is whether hospitals substitute products during the disruption. Elective-procedure consumables and implant workflows are sticky, so a short interruption is likely deferred rather than permanently lost; however, distributor inventory depletion or procedure cancellations could turn this into a 1-2 quarter margin issue through expedited freight, remediation costs, and under-absorption. MDT and ABT are the most plausible share takers in affected categories, but only if they disclose incremental demand or elevated backlog conversion.

The market is likely treating QCOM’s initial price move as a clean AI multiple rerating before contract economics are visible. A more durable rerating requires data-center revenue to scale without materially sacrificing gross margin or requiring repeated equity incentives; conversely, a weak first-quarter contribution or opaque warrant accounting would quickly compress the premium. STZ’s move lacks enough disclosed operating information to support a directional trade; the Barclays discussion is an event risk, not yet a fundamental catalyst.

Key Decisions for Investors

• Initiate a 3-6 month QCOM/AVGO relative-value long QCOM, short AVGO in equal beta-adjusted dollars after the initial gap stabilizes; target 10-15% relative upside if additional hyperscaler wins validate merchant AI silicon. Exit if QCOM’s first disclosed AWS contribution is immaterial, data-center gross margin falls versus corporate margin, or management qualifies the fiscal-2027 target.
• Avoid chasing QCOM outright above the first-day move; use a pullback or sell 3-month downside puts only after confirming the terms and accounting treatment of Amazon’s equity-acquisition right. The missing diligence item is strike price/vesting conditions: economically favorable warrants could materially reduce the apparent value of future revenue.
• Maintain a 1-3 month defensive underweight in SYK versus MDT rather than shorting SYK outright; long MDT/short SYK offers a cleaner expression of potential procedure-share substitution and cyber-recovery cost asymmetry. Cover if SYK reports normalized order fulfillment, no material backlog cancellation, and limited guidance impact.
• Put BSX on an operational-recovery watch rather than initiate a short: evidence of sustained shipment disruption, incremental remediation expense, or a reduction in organic-growth guidance would justify a BSX/ABT relative short. Without those datapoints, pent-up procedure demand could make the selloff reversible.
• No recommended STZ position pending conference disclosures; trigger a review only if management changes depletion, beer-margin, or capital-allocation guidance, as a multi-year-low price alone is not a catalyst.